MIM
EBS icon

MetLife Investment Management’s Emergent Biosolutions EBS Stock Holding History

MetLife Investment Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Sell
25,237
-6,182
-20% -$64K ﹤0.01% 2203
2025
Q4 		$388K Buy
31,419
+4,986
+19% +$53.4K ﹤0.01% 1915
2025
Q3 		$233K Sell
26,433
-6,249
-19% -$48.6K ﹤0.01% 2230
2025
Q2 		$209K Buy
+32,682
New +$187K ﹤0.01% 2165
2024
Q1 		– Sell
-27,395
Closed -$65.7K – 2794
2023
Q4 		$65.7K Hold
27,395
– – ﹤0.01% 2749
2023
Q3 		$93.1K Hold
27,395
– – ﹤0.01% 2616
2023
Q2 		$201K Hold
27,395
– – ﹤0.01% 2274
2023
Q1 		$284K Hold
27,395
– – ﹤0.01% 2001
2022
Q4 		$324K Hold
27,395
– – ﹤0.01% 1919
2022
Q3 		$575K Hold
27,395
– – ﹤0.01% 1535
2022
Q2 		$850K Hold
27,395
– – 0.01% 1295
2022
Q1 		$1.12M Buy
27,395
+9,797
+56% +$432K 0.01% 1258
2021
Q4 		$765K Sell
17,598
-22,960
-57% -$1.04M 0.01% 1254
2021
Q3 		$2.03M Buy
40,558
+201
+0.5% +$12.2K 0.02% 851
2021
Q2 		$2.54M Sell
40,357
-643
-2% -$41.3K 0.02% 766
2021
Q1 		$3.81M Sell
41,000
-2,365
-5% -$242K 0.03% 535
2020
Q4 		$3.89M Sell
43,365
-1,105
-2% -$101K 0.04% 480
2020
Q3 		$4.6M Buy
44,470
+24,459
+122% +$2.64M 0.05% 341
2020
Q2 		$1.58M Hold
20,011
– – 0.02% 827
2020
Q1 		$1.16M Hold
20,011
– – 0.02% 838
2019
Q4 		$1.08M Hold
20,011
– – 0.01% 1063
2019
Q3 		$1.05M Hold
20,011
– – 0.01% 1044
2019
Q2 		$967K Hold
20,011
– – 0.01% 1118
2019
Q1 		$1.01M Hold
20,011
– – 0.01% 1079
2018
Q4 		$1.19M Buy
20,011
+1,170
+6% +$75.4K 0.01% 957
2018
Q3 		$1.24M Sell
18,841
-1,671
-8% -$97.5K 0.01% 1035
2018
Q2 		$1.04M Buy
20,512
+4,795
+31% +$250K 0.01% 1005
2018
Q1 		$828K Hold
15,717
– – 0.01% 1093
2017
Q4 		$730K Buy
+15,717
New +$662K 0.01% 1182

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

MetLife Investment Management's EBS Position: Q1 2026 in Review

MetLife Investment Management reduced its Emergent Biosolutions (EBS) stake by 20% in Q1 2026, selling an estimated $64K and leaving 25,237 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #2203.

MetLife Investment Management first reported a position in EBS in Q4 2017 and has held it in 29 quarters since. The position peaked at $4.6M in Q3 2020. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • MetLife Investment Management held 25,237 shares of Emergent Biosolutions worth $209K as of Q1 2026.
  • MetLife Investment Management sold 6,182 Emergent Biosolutions shares in Q1 2026, an estimated $64K.
  • Emergent Biosolutions made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2203 holding.
  • MetLife Investment Management first reported a position in Emergent Biosolutions in Q4 2017 and has held it in 29 quarters since.
  • MetLife Investment Management's Emergent Biosolutions position peaked at $4.6M in Q3 2020.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.